Aptorum Group Limited (NASDAQ:APM – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 2,482 shares, a decline of 81.4% from the May 14th total of 13,376 shares. Based on an average daily volume of 65,802 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.
Read Our Latest Research Report on Aptorum Group
Aptorum Group Stock Performance
About Aptorum Group
Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.
The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.
Featured Stories
- Five stocks we like better than Aptorum Group
- 3 Stocks Cashing In on AI While Everyone Watches NVIDIA
- 2 Ways to Play the QXO/TopBuild Deal
- Wolfspeed Ditches EV Woes for High-Margin Defense Jets
- Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align
Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.
